Abstract
The role of the transcription factor NF-κB in the pathogenesis of rheumatoid arthritis has long been a subject of controversy. We used an adenoviral technique of blocking NF-κB through overexpression of the inhibitory subunit IκBα, which has the advantage that it can be used in the diseased tissue itself, with >90% of the synovial macrophages, fibroblasts, and T cells infected. We found that the spontaneous production of tumor necrosis factor α and other pro-inflammatory cytokines is NF-κB-dependent in rheumatoid synovial tissue, in contrast to the main anti-inflammatory mediators, like IL-10 and -11, and the IL-1 receptor antagonist. Of even more interest, IκBα overexpression inhibited the production of matrix metalloproteinases 1 and 3 while not affecting their tissue inhibitor. Blocking NF-κB in the rheumatoid joint thus has a very beneficial profile, reducing both the inflammatory response and the tissue destruction. The adenoviral technique described here has widespread applicability, allowing rapid testing of the effects of blocking a potential therapeutic target in either cultures of normal cells or in the diseased tissue itself.
Bibliography
Bondeson, J., Foxwell, B., Brennan, F., & Feldmann, M. (1999). Defining therapeutic targets by using adenovirus: Blocking NF-κB inhibits both inflammatory and destructive mechanisms in rheumatoid synovium but spares anti-inflammatory mediators. Proceedings of the National Academy of Sciences, 96(10), 5668â5673.
References
53
Referenced
174
10.1002/art.1780361206
10.1016/S0140-6736(94)90628-9
10.1093/rheumatology/34.4.334
10.1056/NEJM199707173370301
10.1016/S0065-2776(08)60891-3
10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W
- P L Van Lent, F A Van De Loo, A E Holthuysen, L A Van Den Bersselaar, H Vermeer, W B Van Den Berg J Rheumatol 22, 2250–2258 (1995). / J Rheumatol by Van Lent P L (1995)
10.1002/art.1780370601
- U Muller-Ladner, J Kriegsmann, B N Franklin, S Matsumoto, T Geiler, R E Gay, S Gay Am J Pathol 149, 1607–1615 (1996). / Am J Pathol by Muller-Ladner U (1996)
10.1073/pnas.95.14.8211
-
J Bondeson, K A Brown, F M Brennan, B M J Foxwell, M Feldmann J Immunol 162, 2939–2945 (1999).
(
10.4049/jimmunol.162.5.2939
) / J Immunol by Bondeson J (1999) - G Buchan, K Barrett, M Turner, D Chantry, R N Maini, M Feldmann Clin Exp Immunol 73, 449–455 (1988). / Clin Exp Immunol by Buchan G (1988)
10.1084/jem.183.3.1013
10.1007/BF02789331
10.1002/eji.1830251037
10.1073/pnas.85.8.2603
- I Engelberts, A Moller, G J M Schoen, C J van der Linden, W A Buurman Lymphokine Cytokine Res 10, 60–76 (1991). / Lymphokine Cytokine Res by Engelberts I (1991)
- D M Butler, R N Maini, M Feldmann, F M Brennan Eur Cytokine Network 6, 225–230 (1995). / Eur Cytokine Network by Butler D M (1995)
- J S Abrams, M G Ronocarlo, H Yssel, U Andersson, G I Gleich, J E Silver Immunol Rev 125, 5–24 (1993). / Immunol Rev by Abrams J S (1993)
-
A D Foey, S L Parry, L M Williams, M Feldmann, B M J Foxwell, F M Brennan J Immunol 160, 920–928 (1998).
(
10.4049/jimmunol.160.2.920
) / J Immunol by Foey A D (1998) 10.1002/1529-0131(199808)41:8<1388::AID-ART7>3.0.CO;2-F
10.1146/annurev.iy.12.040194.001041
10.1093/nar/20.7.1531
10.1084/jem.179.5.1517
10.1016/0168-9525(90)90126-Q
10.1002/art.1780360313
10.1002/art.1780380803
10.1093/rheumatology/36.6.643
10.1038/41493
10.1126/science.278.5339.866
10.1128/jvi.69.4.2257-2263.1995
10.1128/jvi.71.10.7663-7669.1997
10.1002/(SICI)1096-9071(199703)51:3<252::AID-JMV18>3.0.CO;2-M
10.1084/jem.174.1.73
10.1146/annurev.immunol.14.1.397
10.1016/S0021-9258(19)36813-9
10.1073/pnas.89.16.7375
10.1073/pnas.89.20.9784
10.1016/S0923-2494(93)80078-D
10.1074/jbc.272.12.7608
10.1042/bj3310453
10.1016/B978-012545090-4/50013-6
10.1002/1529-0131(199805)41:5<869::AID-ART15>3.0.CO;2-3
10.1093/nar/19.13.3723
10.1042/bj3020471
10.1002/1529-0131(199808)41:8<1398::AID-ART8>3.0.CO;2-B
10.1016/0003-9969(96)00148-3
10.1007/s000110050168
10.3181/00379727-218-44293
10.1016/0092-8674(87)90611-8
10.1002/1529-0131(199811)41:11<1987::AID-ART14>3.0.CO;2-8
10.1002/art.1780390407
- M Sioud, O Mellbye, O Forre Clin Exp Rheumatol 16, 125–134 (1998). / Clin Exp Rheumatol by Sioud M (1998)
Dates
Type | When |
---|---|
Created | 23 years, 1 month ago (July 26, 2002, 10:39 a.m.) |
Deposited | 2 years, 4 months ago (April 22, 2023, 8:21 a.m.) |
Indexed | 3 months ago (June 3, 2025, 2:23 p.m.) |
Issued | 26 years, 3 months ago (May 11, 1999) |
Published | 26 years, 3 months ago (May 11, 1999) |
Published Online | 26 years, 3 months ago (May 11, 1999) |
Published Print | 26 years, 3 months ago (May 11, 1999) |
@article{Bondeson_1999, title={Defining therapeutic targets by using adenovirus: Blocking NF-κB inhibits both inflammatory and destructive mechanisms in rheumatoid synovium but spares anti-inflammatory mediators}, volume={96}, ISSN={1091-6490}, url={http://dx.doi.org/10.1073/pnas.96.10.5668}, DOI={10.1073/pnas.96.10.5668}, number={10}, journal={Proceedings of the National Academy of Sciences}, publisher={Proceedings of the National Academy of Sciences}, author={Bondeson, Jan and Foxwell, Brian and Brennan, Fionula and Feldmann, Marc}, year={1999}, month=may, pages={5668–5673} }